In fact, both in vitro and in vivo experiments have shown that KCa3.1-silencing and using KCa3.1 inhibitors (such as TRAM-34) reduced tumor infiltration, glioma-associated microgliosis and astrogliosis, and increased survival time in mouse glioma models (Brown et al. (2018) [70]). Here, KCNN4 is linked to central nervous system cancer.